-- (Updates with 2026 Arcalyst net product revenue guidance in fifth paragraph and latest stock move in the last paragraph.)
Kiniksa Pharmaceuticals (KNSA) reported Q1 earnings Tuesday of $0.27 per share, up from $0.11 a year earlier.
Analysts surveyed by FactSet expected $0.20.
Revenue for the quarter ended March 31 was $214.3 million, up from $137.8 million a year earlier.
Analysts polled by FactSet expected $206.1 million.
The company raised its 2026 Arcalyst net product revenue guidance to a range of $930 million to $945 million, compared with its prior range of $900 million to $920 million. Four analysts polled by FactSet expected $913.3 million.
Shares of the company were up over 16% in Tuesday trading.
Price: $50.86, Change: $+7.25, Percent Change: +16.62%